All Eyes on Biogen as Roche Alzheimer’s Drug Flunks Final Test

Roche this morning added yet another failure to the ever-growing number of experimental Alzheimer’s disease drugs to crumble in late-stage human testing.

The Swiss pharma and partner AC Immune (NASDAQ: ACIU) will stop two Phase 3 studies of their drug crenezumab in Alzheimer’s early after an interim analysis by a committee of investigators showed those trials were likely to fail. No new safety concerns were seen. Roche will share detailed data from the studies, known as CREAD 1 and CREAD 2, at a future medical meeting.